Massive Pulmonary Embolism: What Level of Aggression?

ABSTRACT

Massive pulmonary embolism (PE) with hemodynamic instability (e.g., hypotension and cardiac shock) is associated with a poor prognosis and high mortality rates (> 50%). Accordingly patients with massive PE should be treated aggressively with thrombolytic agents (or surgical or interventional procedures). Streptokinase, urokinase, and recombinant tissue plasminogen activator (rtPA) have been used, with generally similar results. Among patients with submassive PE [i.e., subclinical right ventricular (RV) dysfunction and normal blood pressure], the role of thrombolytic therapy is controversial. Thrombolytic therapy is generally not indicated in normotensive patients without RV dysfunction. In this context, some experts recommend prompt administration of thrombolytic agents to prevent cardiogenic shock but data affirming benefit over heparin alone are lacking. Thrombolytic therapy is generally not indicated in normotensive patients without RV dysfunction. The role of echocardiography, computed tomographic (CT) scans, and cardiac biomarkers (e.g., troponins, brain natriuretic peptide, etc.) to identify patients who might benefit from aggressive thrombolytic therapy remains controversial. This article reviews indications for thrombolysis in massive PE, with an emphasis on recent data derived from normotensive patients. Further, we propose a diagnostic and therapeutic algorithm for treating acute PE. Additional studies are required to determine the benefit and safety of thrombolytic therapy for PE.

Thrombolysis - massive pulmonary embolism - right ventricular dysfunction - urokinase - streptokinase - recombinant tissue thromboplastin activator

REFERENCES

• 1 McIntyre K M, Sasahara A A. Determinants of right ventricular function and hemodynamics after pulmonary embolism.  Chest. 1974;  65 534-543
• 2 McIntyre K M, Sasahara A A. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease.  Am J Cardiol. 1971;  28 288-294
• 3 Lualdi J C, Goldhaber S Z. Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications.  Am Heart J. 1995;  130 1276-1282
• 4 Kasper W, Konstantinides S, Geibel A et al.. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry.  , [see comments] J Am Coll Cardiol. 1997;  30 1165-1171
• 5 European Society of Cardiology TFoPE . Guidelines on diagnosis and management of acute pulmonary embolism.  Eur Heart J. 2000;  21 1301-1336
• 6 British Thoracic Society . Guidelines for the management of suspected acute pulmonary embolism.  Thorax. 2003;  58 470-483
• 7 Kucher N, Goldhaber S Z. Management of massive pulmonary embolism.  Circulation. 2005;  112 e28-e32
• 8 Dalen J E. Thrombolysis in submassive pulmonary embolism? No.  J Thromb Haemost. 2003;  1 1130-1132
• 9 Konstantinides S. Thrombolysis in submassive pulmonary embolism? Yes.  J Thromb Haemost. 2003;  1 1127-1129
• 10 Goldhaber S Z. Thrombolytic therapy for patients with pulmonary embolism who are hemodynamically stable but have right ventricular dysfunction: pro.  Arch Intern Med. 2005;  165 2197-2199
• 11 Thabut G, Logeart D. Thrombolysis for pulmonary embolism in patients with right ventricular dysfunction: con.  Arch Intern Med. 2005;  165 2200-2203
• 12 The urokinase pulmonary embolism trial: a national cooperative study.  Circulation. 1973;  47 II1-108
• 13 Tibbutt D A, Davies J A, Anderson J A et al.. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism.  BMJ. 1974;  1 343-347
• 14 Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism.  Acta Med Scand. 1978;  203 465-470
• 15 Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial.  Respiration. 1988;  54 162-173
• 16 Levine M, Hirsh J, Weitz J et al.. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.  Chest. 1990;  98 1473-1479
• 17 The PIOPED Investigators . Tissue plasminogen activator for the treatment of acute pulmonary embolism: a collaborative study.  Chest. 1990;  97 528-533
• 18 Dalla-Volta S, Palla A, Santolicandro A et al.. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: plasminogen activator Italian multicenter study 2.  J Am Coll Cardiol. 1992;  20 520-526
• 19 Goldhaber S Z, Haire W D, Feldstein M L et al.. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion.  Lancet. 1993;  341 507-511
• 20 Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism.  Am J Cardiol. 1998;  82 966-970
• 21 Urokinase-streptokinase embolism trial: phase 2 results: a cooperative study.  JAMA. 1974;  229 1606-1613
• 22 Meyer G, Sors H, Charbonnier B et al.. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism.  , [see comments] J Am Coll Cardiol. 1992;  19 239-245
• 23 Goldhaber S Z, Kessler C M, Heit J et al.. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.  Lancet. 1988;  2 293-298
• 24 Meneveau N, Schiele F, Metz D et al.. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up.  J Am Coll Cardiol. 1998;  31 1057-1063
• 25 Meneveau N, Schiele F, Vuillemenot A et al.. Streptokinase vs alteplase in massive pulmonary embolism: a randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction.  Eur Heart J. 1997;  18 1141-1148
• 26 Goldhaber S Z, Agnelli G, Levine M N. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.  Chest. 1994;  106 718-724
• 27 Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism: a randomized controlled multicenter trial.  Chest. 1994;  106 712-717
• 28 Verstraete M, Miller G A, Bounameaux H et al.. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism.  Circulation. 1988;  77 353-360
• 29 Tebbe U, Graf A, Kamke W et al.. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism.  Am Heart J. 1999;  138 39-44
• 30 Kline J A, Hernandez-Nino J, Jones A E. Tenecteplase to treat pulmonary embolism in the emergency department.  J Thromb Thrombolysis. 2007;  23 101-105
• 31 Meneveau N, Seronde M F, Blonde M C et al.. Management of unsuccessful thrombolysis in acute massive pulmonary embolism.  Chest. 2006;  129 1043-1050
• 32 Daniels L B, Parker J A, Patel S R, Grodstein F, Goldhaber S Z. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism.  Am J Cardiol. 1997;  80 184-188
• 33 Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism.  N Engl J Med. 2002;  347 1143-1150
• 34 Kanter D S, Mikkola K M, Patel S R, Parker J A, Goldhaber S Z. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors.  Chest. 1997;  111 1241-1245
• 35 Goldhaber S Z, Kessler C M, Heit J A et al.. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial.  J Am Coll Cardiol. 1992;  20 24-30
• 36 Stein P D, Hull R D, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism: consideration of noninvasive management.  , [see comments] Ann Intern Med. 1994;  121 313-317
• 37 Wan S, Quinlan D J, Agnelli G, Eikelboom J W. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials.  Circulation. 2004;  110 744-749
• 38 Kasper W, Konstantinides S, Geibel A et al.. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry.  J Am Coll Cardiol. 1997;  30 1165-1171
• 39 Kucher N, Rossi E, De Rosa M, Goldhaber S Z. Massive pulmonary embolism.  Circulation. 2006;  113 577-582
• 40 Stein P D, Henry J W. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy.  Chest. 1995;  108 978-981
• 41 Jerjes-Sanchez C, Ramírez-Rivera A, de Lourdes G et al.. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial.  J Thromb Thrombolysis. 1995;  2 227-229
• 42 Rose P S, Punjabi N M, Pearse D B. Treatment of right heart thromboemboli.  Chest. 2002;  121 806-814
• 43 Chartier L, Bera J, Delomez M et al.. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients.  Circulation. 1999;  99 2779-2783
• 44 Grifoni S, Olivotto I, Cecchini P et al.. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction.  Circulation. 2000;  101 2817-2822
• 45 Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism.  Heart. 1997;  77 346-349
• 46 Vieillard-Baron A, Page B, Augarde R et al.. Acute cor pulmonale in massive pulmonary embolism: incidence, echocardiographic pattern, clinical implications and recovery rate.  Intensive Care Med. 2001;  27 1481-1486
• 47 Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis.  , [see comments] Circulation. 1999;  99 1325-1330
• 48 Kucher N, Rossi E, De Rosa M, Goldhaber S Z. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher.  Arch Intern Med. 2005;  165 1777-1781
• 49 ten Wolde M, Sohne M, Quak E, Mac Gillavry M R, Buller H R. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism.  Arch Intern Med. 2004;  164 1685-1689
• 50 Kasper W, Geibel A, Tiede N et al.. Distinguishing between acute and subacute massive pulmonary embolism by conventional and Doppler echocardiography.  Br Heart J. 1993;  70 352-356
• 51 Schoepf U J, Kucher N, Kipfmueller F, Quiroz R, Costello P, Goldhaber S Z. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism.  Circulation. 2004;  110 3276-3280
• 52 van der Meer R W, Pattynama P M, van Strijen M J et al.. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism.  Radiology. 2005;  235 798-803
• 53 Perrier A, Roy P M, Sanchez O et al.. Multidetector-row computed tomography in suspected pulmonary embolism.  N Engl J Med. 2005;  352 1760-1768
• 54 Janata K, Holzer M, Laggner A N, Mullner M. Cardiac troponin T in the severity assessment of patients with pulmonary embolism: cohort study.  BMJ. 2003;  326 312-313
• 55 Pruszczyk P, Bochowicz A, Torbicki A et al.. Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism.  Chest. 2003;  123 1947-1952
• 56 Konstantinides S, Geibel A, Olschewski M et al.. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism.  Circulation. 2002;  106 1263-1268
• 57 Giannitsis E, Muller-Bardorff M, Kurowski V et al.. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism.  Circulation. 2000;  102 211-217
• 58 Kucher N, Goldhaber S Z. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism.  Circulation. 2003;  108 2191-2194
• 59 Bova C, Crocco F, Ricchio R, Serafini O, Greco F, Noto A. Importance of troponin T for the risk stratification of normotensive patients with pulmonary embolism: a prospective, cohort study with a three-month follow-up.  Haematologica. 2005;  90 423-424
• 60 La Vecchia L, Ottani F, Favero L et al.. Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism.  Heart. 2004;  90 633-637
• 61 Yalamanchili K, Sukhija R, Aronow W S, Sinha N, Fleisher A G, Lehrman S G. Prevalence of increased cardiac troponin I levels in patients with and without acute pulmonary embolism and relation of increased cardiac troponin I levels with in-hospital mortality in patients with acute pulmonary embolism.  Am J Cardiol. 2004;  93 263-264
• 62 Binder L, Pieske B, Olschewski M et al.. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism.  Circulation. 2005;  112 1573-1579
• 63 Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess O M. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism.  Circulation. 2003;  107 1576-1578
• 64 Kucher N, Printzen G, Goldhaber S Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism.  Circulation. 2003;  107 2545-2547
• 65 Pruszczyk P, Kostrubiec M, Bochowicz A et al.. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism.  Eur Respir J. 2003;  22 649-653
• 66 ten Wolde M, Tulevski I I, Mulder J W et al.. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism.  Circulation. 2003;  107 2082-2084
• 67 Krüger S, Graf J, Merx M W et al.. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism.  Am Heart J. 2004;  147 60-65
• 68 Giannitsis E, Katus H A. Risk stratification in pulmonary embolism based on biomarkers and echocardiography.  Circulation. 2005;  112 1520-1521
• 69 Storch J, Thumser A E. The fatty acid transport function of fatty acid-binding proteins.  Biochim Biophys Acta. 2000;  1486 28-44
• 70 Alhadi H A, Fox K A. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein.  QJM. 2004;  97 187-198
• 71 Pelsers M M, Hermens W T, Glatz J F. Fatty acid-binding proteins as plasma markers of tissue injury.  Clin Chim Acta. 2005;  352 15-35
• 72 Puls M, Dellas C, Lankeit M et al.. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism.  Eur Heart J. 2007;  28 224-229
• 73 Kaczynska A, Pelsers M M, Bochowicz A, Kostrubiec M, Glatz J F, Pruszczyk P. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism.  Clin Chim Acta. 2006;  371 117-123
• 74 Scridon T, Scridon C, Skali H, Alvarez A, Goldhaber S Z, Solomon S D. Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism.  Am J Cardiol. 2005;  96 303-305